Introduction {#s1}
============

Bipolar disorder I (BDI) is an episodic illness characterized by recurrent manic, mixed, and depressive episodes with an estimated global lifetime prevalence of 1--5% [@pone.0100634-Kastrup1]. BDI is associated with a high prevalence of mortality and morbidity [@pone.0100634-Rush1], functional impairment [@pone.0100634-Rosa1], and suicide [@pone.0100634-Association1]. Mania is a core aspect of the presentation of BDI, but the pathophysiology of manic syndrome is poorly understood. Recent evidence suggests that atypical antipsychotics are effective for the treatment of manic syndrome [@pone.0100634-Vieta1], [@pone.0100634-Yatham1]. Moreover, it is known that levels of the metabolites of noradrenaline and dopamine, 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA), respectively, are higher in bipolar manic patients more than in normal control [@pone.0100634-Azorin1], [@pone.0100634-Yoshimura1], are reduced by treatment with antipsychotic agents [@pone.0100634-Yoshimura1]. However, several reports have suggested that antipsychotics can induce depression or extrapyramidal symptoms (EPS) in bipolar manic patients [@pone.0100634-Tohen1], [@pone.0100634-White1], [@pone.0100634-Kukopulos1]. Thus, whether the decreased levels of MHPG and HVA are caused by the carryover effect of antipsychotics or by the pathophysiology of BDI is not known.

Furthermore, a meta-analysis showed that brain-derived neurotrophic factor (BDNF) levels were decreased in bipolar mania and bipolar depression when compared with both control groups [@pone.0100634-Fernandes1]. It is also not clear whether the decreased levels of BDNF are caused by the carryover effect of antipsychotics or by the pathophysiology of BDI. Thus, the association of BDI with peripheral biomarkers in the pathophysiology of BDI is not clear. Currently, there is no biomarker that could serve as an objective index for evaluating the severity of BDI or whether a particular treatment will be effective for BDI.

The main purpose of the present study was to ascertain if plasma levels of catecholamine metabolites and BDNF are correlated with the severity of manic symptoms in BDI, and to understand the pathophysiology of BDI. We focused on the correlation of biomarkers and symptoms, not the effects of medication upon biomarkers. Our report is the first naturalistic, retrospective study examining levels of MHPG (a noradrenaline metabolite associated with noradrenaline levels in the brain), HVA (a dopamine metabolite associated with dopamine levels in the brain) and BDNF in manic states of BDI.

Methods {#s2}
=======

Subjects {#s2a}
--------

A detailed flowchart of patient selection is shown in [Fig. 1](#pone-0100634-g001){ref-type="fig"}. Subjects were recruited from BPI patients admitted to the inpatient and outpatient clinics of Sato Hospital (Koutokukai, Japan) between June 2006 and August 2010. All patients were suffering from a manic episode according to the diagnosis of BDI stated in the *Diagnostic and Statistical Manual for Mental Disorders* (fourth edition, text version, DSM-IV-TR, American Psychiatric Association, 2000). Subjects with any other diagnosed mental or severe physical illness were excluded from the study. Patients were also excluded if they exhibited a borderline personality disorder, antisocial personality disorder, or if they had a history of substance dependence.

![Flowchart of patient numbers through the study.](pone.0100634.g001){#pone-0100634-g001}

After the procedures had been explained fully to them, participants provided written informed consent. Study protocols were approved by the Ethics Committee of Sato Hospital and the Ethics Committee of the Graduate School of Pharmaceutical Sciences of Tohoku University (Sendai, Japan). Standard procedures for clinical trials involving vulnerable participants in Japan were followed. This study was undertaken according to the ethical standards set in the Declaration of Helsinki. Patients who declined to participate or who otherwise did not take part remained eligible for treatment, and were not disadvantaged in any way by not participating in the study.

As a criterion for patient inclusion, we chose a Young Mania Rating Scale (YMRS) score of ≥20 points as the manic syndrome stage [@pone.0100634-Calabrese1]. In addition, patients were considered to be in remission if they scored ≤8 on the Montgomery--Åsberg Depression Rating Scale (MADRS) [@pone.0100634-Montgomery1] and YMRS [@pone.0100634-Young1], [@pone.0100634-Monteleone1]. The response stage was defined as a reduction of \<50% in YMRS score from the manic syndrome stage. The final analyses comprised 24 BDI patients (13 men and 11 women; average age, 54.5±16.0 (range, 24--79) years).

None of the subjects were taking hormone therapies (including oral contraceptives). Dosage and administration of antihypertensive medications were unchanged during this study. The following antihypertensive medications were administered during this study: amlodipine (5 mg/day; n = 2), lisinopril (20 mg/day; n = 1) and nifedipine (20 mg/day; n = 1). One patient was administered acetaminophen (450 mg/day; n = 1) temporarily during the responder state. Most patients (22/24) had been prescribed mood stabilizers and/or antipsychotic drugs by psychiatrists. Psychiatrists treated patients with brief sessions of psychotherapy. The following mood stabilizers and antipsychotic drugs were administered in the manic syndrome stage: lithium (200--800 mg/day; n = 8), valproic acid (400--1600 mg/day; n = 16), lamotrigine (100 mg/day; n = 1), carbamazepine (400 mg/day; n = 1), risperidone (1.5--4 mg/day; n = 4), quetiapine (50--200 mg/day; n = 2), chlorpromazine (12.5--150 mg/day; n = 3), propericiazine (10--30 mg/day; n = 2), levomepromazine (5--50 mg/day; n = 6), zotepine (150 mg/day; n = 1) and aripiprazole (18 mg/day; n = 1). The mean dose at the syndrome stage for chlorpromazine equivalence [@pone.0100634-Andreasen1] was 116±145 mg/day. Eight patients were not taking antipsychotics at the syndrome stage. The following mood stabilizers and antipsychotic drugs were administered in the response stage: lithium (300--800 mg/day; n = 8), valproic acid (200--2000 mg/day; n = 17), lamotrigine (100 mg/day; n = 1), carbamazepine (400 mg/day; n = 2), risperidone (1.5--16 mg/day; n = 3), quetiapine (50--600 mg/day; n = 2), chlorpromazine (37.5 mg/day; n = 1), propericiazine (15 mg/day; n = 1), levomepromazine (5--150 mg/day; n = 6), zotepine (50--400 mg/day; n = 2), aripiprazole (12 mg/day; n = 1), blonanserin (4 mg/day; n = 1) and sultopride (300 mg/day; n = 1). The mean dose at the response stage for chlorpromazine equivalence was 187±473 mg/day. Eleven patients were not taking antipsychotics at the response stage. The following mood stabilizers and antipsychotic drugs were administered in the remission stage: lithium (300--800 mg/day; n = 9), valproic acid (200--2000 mg/day; n = 18), lamotrigine (100 mg/day; n = 1), carbamazepine (400 mg/day; n = 1), risperidone (0.5--16 mg/day; n = 3), quetiapine (50 mg/day; n = 1), propericiazine (10 mg/day; n = 1), levomepromazine (5--80 mg/day; n = 5), zotepine (50--400 mg/day; n = 2), aripiprazole (12 mg/day; n = 1) and sultopride (100 mg/day; n = 1). The mean dose at the remission stage for chlorpromazine equivalence was 134±448 mg/day. Thirteen patients were not taking antipsychotics at the remission stage ([Table 1](#pone-0100634-t001){ref-type="table"}).

10.1371/journal.pone.0100634.t001

###### Medications taken by study patients.

![](pone.0100634.t001){#pone-0100634-t001-1}

                Syndrome       (mg)      Response       (mg)      Remission      (mg)
  --------- ----------------- ------ ----------------- ------ ----------------- ------
  Case 1           \-                       \-                       \-         
  Case 2         lithium       200     valproic acid    200     valproic acid    200
              valproic acid    600                                              
               risperidone      4                                               
  Case 3         lithium       800        lithium       800        lithium       800
              valproic acid    800     valproic acid    1200    valproic acid    1200
             levomepromazine    50    levomepromazine    50    levomepromazine    50
  Case 4           \-                       \-                       \-         
  Case 5      valproic acid    1200       lithium       600        lithium       600
             chlorpromazine    150     valproic acid    1200    valproic acid    1200
                                       aripiprazole      12     aripiprazole      12
  Case 6         lithium       800        lithium       800        lithium       800
             chlorpromazine    37.5   chlorpromazine    37.5   chlorpromazine     10
             levomepromazine    10    levomepromazine    10                     
  Case 7         lithium       300     carbamazepine    400     valproic acid    400
              aripiprazole      18                                              
  Case 8         lithium       500        lithium       600        lithium       600
              valproic acid    600     valproic acid    800     valproic acid    800
               risperidone     1.5      risperidone     1.5      risperidone      2
  Case 9      valproic acid    1000    valproic acid    1600    valproic acid    1600
  Case 10        lithium       600        lithium       400        lithium       400
              valproic acid    600     valproic acid    600     valproic acid    600
             propericiazine     30    propericiazine     15    propericiazine     10
             levomepromazine    50      sultopride      300      sultopride      100
                                      levomepromazine   150    levomepromazine    75
  Case 11        lithium       400        lithium       400        lithium       400
              valproic acid    800     valproic acid    400     valproic acid    400
             propericiazine     10    levomepromazine    10                     
             levomepromazine    25                                              
  Case 12     valproic acid    1600    valproic acid    2000    valproic acid    2000
               quetiapine      200      quetiapine      600                     
  Case 13      lamotrigine     100      lamotrigine     100      lamotrigine     100
               quetiapine       50      quetiapine       50      quetiapine       50
  Case 14     valproic acid    1200    valproic acid    800     valproic acid    800
  Case 15        lithium       800        lithium       400        lithium       400
              valproic acid    1000    valproic acid    1000    valproic acid    1000
             chlorpromazine    12.5                                             
  Case 16          \-                  valproic acid    1000    valproic acid    1200
  Case 17     carbamazepine    400     carbamazepine    400     carbamazepine    400
             levomepromazine    35    levomepromazine    80        lithium       600
                                                               levomepromazine    80
  Case 18     valproic acid    1400    valproic acid    1000    valproic acid    1000
  Case 19     valproic acid    1200    valproic acid    1500    valproic acid    1400
  Case 20     valproic acid    1000    valproic acid    1200    valproic acid    1200
             levomepromazine    5       blonanserin      4     levomepromazine    5
                                      levomepromazine    5                      
  Case 21      risperidone      2       risperidone      1       risperidone     0.5
  Case 22     valproic acid    900     valproic acid    900     valproic acid    900
  Case 23     valproic acid    1100       lithium       300        lithium       300
                zotepine       150     valproic acid    1200    valproic acid    1200
                                         zotepine        50       zotepine        50
  Case 24     valproic acid    400     valproic acid    1600    valproic acid    1600
               risperidone      4       risperidone      16      risperidone      16
                                         zotepine       400       zotepine       400

Assessment {#s2b}
----------

The clinical status of patients was evaluated using the YMRS [@pone.0100634-Young1] and MADRS [@pone.0100634-Montgomery1]. Symptom severity was assessed every two weeks by independent experienced raters using the YMRS and MADRS. Raters were blinded to the treatment the participants had been receiving and were not associated with treatment administration.

Sample Collection {#s2c}
-----------------

Blood sampling and mood assessments were carried out at the same time of day every two weeks. Blood was drawn from each subject by venipuncture into a blood-collection tube containing the anticoagulant ethylenediamine tetra-acetic acid between 10:00 and 17:00. Tubes were cooled immediately to 4°C and then centrifuged at 2000× *g* for 20 min. Plasma was kept at −80°C until assay.

Laboratory Assays {#s2d}
-----------------

Plasma levels of MHPG and HVA were analyzed by high-performance liquid chromatography with electrochemical detection [@pone.0100634-Yeung1], [@pone.0100634-Yoshimura2] using internal-standard (5-hydroxyindolecarboxylic acid) and standard-addition methods. Plasma levels of BDNF were analyzed by sandwich enzyme-linked immunosorbent assay as described previously [@pone.0100634-Kurita1].

Data Analyses {#s2e}
-------------

Statistical analyses of MADRS and YMRS scores and plasma levels of MHPG, HVA and BDNF were undertaken using one-way repeated-measures analyses of variance (rep-ANOVA) for the three stages of symptoms. *Post hoc* tests were carried out on rep-ANOVA results using the Bonferroni correction for multiple comparisons. Data are the means ± standard deviation (mean ± SD). Correlation analyses were done using Spearman\'s correlation (ρ). *p*\<0.05 was considered significant. Testing for normal distribution of data was undertaken using Mauchly\'s sphericity test. Analyses were carried out using SPSS v16.0 (SPSS, Chicago, IL, USA).

Trial Registration {#s2f}
------------------

This study is registered in the UMIN Clinical Trials Registry (UMIN-CTR): Analysis of genome and blood components for elucidation and treatment of mood disorders ([ctr.cgi&quest;function&hairsp;&equals;&hairsp;brows&amp;action&hairsp;&equals;&hairsp;brows&amp;recptno&hairsp;&equals;&hairsp;R000007415&amp;type&hairsp;&equals;&hairsp;summary&amp;language&hairsp;&equals;&hairsp;E](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000007415&type=summary&language=E); UMIN000006264).

Results {#s3}
=======

Assessment {#s3a}
----------

We used the YMRS score to separate stages (i.e., manic syndrome, response, remission). The manic syndrome stage was defined as a YMRS of ≥20 points [@pone.0100634-Calabrese1]. The response stage was defined as a reduction in the YMRS score of \<50% from the manic syndrome stage. The remission stage was defined as a YMRS score ≤8 [@pone.0100634-Young1], [@pone.0100634-Monteleone1]. Mean YMRS scores for manic syndrome, response, and remission stages were 32.5±8.3, 6.4±5.9, and 1.9±2.7, respectively. Consequently, patients in the remission group had significantly reduced YMRS scores during treatment (repeated-measures ANOVA; F~2,46~ = 224.823, *p*\<0.001). There were significant differences in YMRS scores among stages (manic syndrome *vs* response (*p*\<0.001), manic syndrome *vs* remission (*p*\<0.001), and response *vs* remission (*p* = 0.007); Bonferroni\'s multiple comparison). Patients exhibited no significant changes in MADRS score among manic syndrome, response and remission stages (0.7±1.5, 1.5±2.4, and 1.7±2.3, respectively) (repeated-measures ANOVA; F~2,46~ = 2.310, *p* = 0.111). The period from the manic syndrome stage to the response stage was 3.4±2.4 weeks. The period from the manic syndrome stage to the remission stage was 5.8±3.2 weeks ([Table 2](#pone-0100634-t002){ref-type="table"}).

10.1371/journal.pone.0100634.t002

###### Mean changes in outcome measures.

![](pone.0100634.t002){#pone-0100634-t002-2}

                                        Syndrome       Response      Remission       *p*    
  ---------------------------------- -------------- -------------- -------------- --------- --------
  Period from the syndrome (weeks)     3.4 (2.4)      5.8 (3.2)                             
  Assessments                                                                               
  **YMRS** (points)                    32.5 (8.3)     6.4 (5.9)      1.9 (2.7)     \<0.001   \*\*\*
  **MADRS** (points)                   0.7 (1.5)      1.5 (2.4)      1.7 (2.3)      0.111   
  Biological markers                                                                        
  **MHPG** (ng/mL)                    10.14 (2.85)   9.70 (2.93)    8.33 (2.20)     0.002     \*\*
  **HVA** (ng/mL)                     11.54 (4.36)   11.72 (7.65)   10.02 (4.44)    0.273   
  **BDNF** (pg/mL)                    5493 (4905)    6611 (4822)    6619 (4709)     0.293   

Values are the mean (SD).

Statistical analyses were carried out using one-way repeated measures analysis of variance.

Statistically significant (\*\**p*\<0.01, \*\*\**p*\<0.001).

YMRS, Young Mania Rating Scale; MADRS, Montgomery--Åsberg Depression Rating Scale; MHPG, 3-methoxy-4-hydroxyphenylglycol; HVA, homovanillic acid;

BDNF, brain-derived neurotrophic factor.

Biological Markers {#s3b}
------------------

Plasma levels of MHPG in manic syndrome, response and remission stages were 10.1±2.9, 9.7±2.9, and 8.3±2.2 ng/mL, respectively. Patients had significantly reduced plasma levels of MHPG throughout the manic syndrome, response and remission stages (repeated-measures ANOVA; F~2,46~ = 7.370, *p* = 0.002) ([Fig. 2](#pone-0100634-g002){ref-type="fig"}). There were significant differences in plasma levels of MHPG among stages (manic syndrome *vs* response (*p* = 0.871), manic syndrome *vs* remission (*p* = 0.006), and response *vs* remission (*p* = 0.054); Bonferroni\'s multiple comparison).

![Changes in plasma levels of MHPG in the manic state for BDI patients.\
Each point represents the mean value. The significance of differences was calculated using repeated-measures ANOVA with *post hoc* Bonferroni testing (\**p*\<0.05). Patients had significantly reduced plasma levels of MHPG throughout the manic syndrome, response and remission stages (repeated-measures ANOVA; F~2,46~ = 7.370, *p* = 0.002).](pone.0100634.g002){#pone-0100634-g002}

Treatment of BDI led to an expected decrease in YMRS scores, and this was accompanied by a significant decrease in plasma levels of MHPG. A trend for positive correlation was found between YMRS scores and plasma levels of MHPG throughout the manic syndrome, response and remission stages (ρ = 0.214, *p* = 0.071, n = 72). In the case of taking into account only the manic syndrome and remission stages, there was a significant positive correlation between YMRS scores and plasma levels of MHPG (ρ = 0.33, *p* = 0.033, n = 48). In contrast, patients exhibited no significant changes in plasma levels of HVA or BDNF throughout the manic syndrome, response and remission stages (repeated-measures ANOVA; F~2,46~ = 1.334, *p* = 0.273; F~2,46~ = 1.261, *p* = 0.293). No significant correlation was found between plasma levels of HVA or BDNF and the manic state ([Table 2](#pone-0100634-t002){ref-type="table"}).

Discussion {#s4}
==========

In the present study, we focused on the pathophysiology of BDI. An advantage of our naturalistic study was that we could compare the multifaceted biomarkers between manic states. Antipsychotics [@pone.0100634-Yildiz1] and mood stabilizers [@pone.0100634-Macritchie1] have good efficacy in controlling manic syndrome in BDI patients.

Several reports have suggested that the BDNF system might change individual susceptibility to BDI [@pone.0100634-Fernandes1], [@pone.0100634-Kapczinski1]. Also, some studies have shown levels of MHPG and HVA to be decreased after antipsychotic treatments in BDI patients [@pone.0100634-Yoshimura1] and psychotic patients [@pone.0100634-Bowers1]. Thus, the association between BDI and peripheral biomarkers is not consistent with respect to the pathophysiology of BDI.

For the first time in the literature, patients in the manic state of BDI underwent evaluation of levels of MHPG, HVA and BDNF in a naturalistic study. Interestingly, BDI patients had significantly reduced plasma levels of MHPG throughout manic syndrome, response and remission stages. Conversely, no significant changes were observed between plasma levels of HVA or BDNF ([Table 2](#pone-0100634-t002){ref-type="table"}). In the case of taking into account only the manic syndrome and remission stages, we found a significant positive correlation between YMRS scores and plasma levels of MHPG. However, only a trend for positive correlation was found between YMRS scores and plasma levels of MHPG within the three states. BDI patients had significantly reduced plasma levels of MHPG throughout the three states, but the response state may be dependent upon the individual. These results suggest that the plasma level of MHPG acted as a peripheral biomarker, consistently indicating the synchronized progression of symptoms from the manic state to the remission state in BDI. MHPG is the major metabolite of noradrenaline in the brain [@pone.0100634-Schanberg1]. In the present study, only the plasma level of MHPG exhibited significant changes that correlated with the YMRS score among stages. The results of the present study suggest that changes in the noradrenergic system are more likely than changes in the dopaminergic and BDNF systems to improve manic syndrome in BDI.

Antipsychotics can induce depression or EPS in bipolar manic patients [@pone.0100634-Tohen1], [@pone.0100634-White1], [@pone.0100634-Kukopulos1]. Hence, antipsychotics are a temporary treatment in severe manic cases, and clinicians know that there is an increased risk of depression or EPS if high doses of antipsychotics are continued to be prescribed. In the present study, the mean dose at remission for chlorpromazine equivalence [@pone.0100634-Andreasen1] was 134±448 mg/day. In studies involving decreased levels of MHPG and HVA, the mean doses for chlorpromazine equivalence [@pone.0100634-Andreasen1] were 380±110 and 300--600 (for a 60-kg body weight) mg/day, respectively [@pone.0100634-Yoshimura1], [@pone.0100634-Bowers1]. Further studies are needed to ascertain if decreased levels of MHPG and HVA are due to the carryover effects of antipsychotics. With respect to chlorpromazine equivalence, this study suggests that the effects of antipsychotics are slight. In addition, of the 24 patients in the present study, the number of subjects not taking antipsychotics increased from 8 patients in the syndrome stage to 13 patients in the remission stage. In summary, the result of decreased plasma levels of MHPG may reflect the pathophysiology from manic to remission states.

This study had limitations. One was the lack of a control group with placebo treatments. However, even though most treatments involved mood stabilizers in the remission state, plasma levels of MHPG continued to decline. Blood was drawn from individual patients in the same time zone as much as possible, but could not be withdrawn from all patients in the same time zone. Plasma levels of MHPG do not change a great deal within the active phase [@pone.0100634-Koenigsberg1]. On the other hand, phase advance in diurnal MHPG rhythm repoted in depression [@pone.0100634-Gwirtsman1]. Conversely, diurnal variation in plasma levels of BDNF may be associated with differences between the sexes [@pone.0100634-Choi1], [@pone.0100634-Piccinni1]. The half-life in the human brain is 88.4 h for olanzapine and 45.5 h for risperidone [@pone.0100634-Tauscher1], so the carryover effects of antipsychotics may not have occurred in the present study. More large-scale design follow-up studies are needed to understand the pathologic state for the treatment of BDI.

Conclusions {#s5}
===========

These data suggest that the peripheral level of MHPG (which is associated with noradrenaline levels in the brain) could be used as a biomarker for manic states in BDI. The MHPG level is likely to reflect the severity of the manic state in BDI, and noradrenaline may reflect the pathophysiology from manic to remission states. The MHPG level could be markedly different from individual to individual. Therefore, it is important that the MHPG level of an individual patient is known because it may change over time.
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